Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of niraparib in participants benefiting from prior GSK/TESARO parent studies
MOH_2021-06-02_009873Phase 2Not yet recruiting
- Sponsor
- GSK
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib in ovarian cancer, sponsored by GSK. Primary endpoint: Long-term safety and tolerability of niraparib. Planned start May 2021; status: not yet recruiting.
02
Drugs
niraparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on MOH_2021-06-02_009873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-06-02_009873.